ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction

Clinical Standards Committee

The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is a scientific organization that encourages sound clinical practice, and high-quality teaching and research related to diagnostic imaging in women's healthcare. The ISUOG Clinical Standards Committee (CSC) has a remit to develop Practice Guidelines and Consensus Statements as educational recommendations that provide healthcare practitioners with a consensus-based approach, from experts, for diagnostic imaging. They are intended to reflect what is considered by ISUOG to be the best practice at the time at which they are issued. Although ISUOG has made every effort to ensure that Guidelines are accurate when issued, neither the Society nor any of its employees or members accepts any liability for the consequences of any inaccurate or misleading data, opinions or statements issued by the CSC. The ISUOG CSC documents are not intended to establish a legal standard of care, because interpretation of the evidence that underpins the Guidelines may be influenced by individual circumstances, local protocol and available resources. Approved Guidelines can be distributed freely with the permission of ISUOG (info@isuog.org).

INTRODUCTION

The evaluation of fetal growth is one of the key objectives of prenatal care. Fetal growth depends on several factors, including uteroplacental function, maternal disease, maternal cardiovascular function or cardiac disease, maternal nutrition, altitude, smoking and illicit drug use, and presence of pathological conditions, such as infection, aneuploidy and some genetic conditions. However, uteroplacental insufficiency or dysfunction represents one of the most frequent causes of abnormal growth in an otherwise normal fetus.

Impaired fetal growth is associated with an increased risk of perinatal mortality and morbidity, and long-term adverse infant outcome. Overall, growth-restricted fetuses have a higher rate of conditions associated with prematurity, experience worse neurodevelopmental outcome and are at increased risk of non-communicable diseases in adulthood, such as hypertension, metabolic syndrome, insulin resistance, Type-2 diabetes mellitus, coronary heart disease and stroke. Prenatal recognition of fetal growth restriction (FGR) is a major factor identified in strategies aimed at preventing stillbirth, in which up to 30% of cases are associated with FGR or small-for-gestational age (SGA) in the late third trimester.

This Guideline provides definitions of FGR, previously referred to as intrauterine growth restriction, and SGA, and describes the best possible management options based on current data and knowledge. For the purposes of this Guideline, we assume that the pregnancy is singleton, pregnancy dating has been carried out correctly (preferably in the first trimester by ultrasound) and that there are no fetal pathologies, such as aneuploidy, congenital malformation or infection. Details of the grades of recommendation used in this Guideline are provided in Appendix 1. Reporting of levels of evidence is not applicable to this Guideline.

GUIDELINE

Definition of and distinction between small-for-gestational age and fetal growth restriction

Fetal growth is a dynamic process and its assessment requires multiple observations of fetal size over time. Fetal size is determined through biometric evaluation of the head circumference, biparietal diameter, abdominal circumference (AC) and femur length and/or derivation of estimated fetal weight (EFW) computed by different formulae. The ISUOG Guidelines on ultrasound assessment of fetal biometry and growth describe methodology, reference ranges, growth standards and quality-control processes for appropriate assessment of fetal biometry and diagnosis of fetal growth disorders. Controversies in relation to reference ranges and other issues related to the assessment of fetal biometry are described in this Guideline.

A fetus is considered to be SGA when its size (biometric evaluation) falls below a predefined threshold for its gestational age. The most common definition of SGA is EFW or AC below the 10th percentile of given
FGR is a condition that is frequently, but unhappily, defined as the fetus failing to reach its genetically predetermined growth potential. The identification of FGR is often not straightforward as fetal growth cannot be assessed through a single biometric evaluation of the fetal size, and growth potential is hypothetical.

The main distinction between SGA and FGR is that a SGA fetus may be small but not at increased risk of adverse perinatal outcome, while a fetus with size above the 10th percentile may be FGR and at increased risk of adverse perinatal and long-term outcome.

Fetuses with birth weight below the 10th percentile are at increased risk of stillbirth and perinatal mortality, with those with birth weight below the 3rd percentile being at the highest risk. For this reason, fetal size at the lower extreme of the growth charts, for example AC or EFW below the 3rd percentile for given growth charts, can be used as an isolated criterion to define FGR at any gestational epoch. In fact, the optimal size at birth that is associated with the lowest perinatal mortality seems to be substantially higher than the median birth weight of a normal cohort. In a population-based cohort study found increased perinatal mortality even in fetuses with birth weight within the normal range, with those with birth weight between the 70th and 90th percentiles being at the lowest risk, and an inverse association between perinatal mortality and birth weight below the 80th percentile.

A large Scottish population-based cohort study demonstrated a progressive increase in the risk of stillbirth in pregnancies with a predicted birth weight below the 25th percentile.

In order to differentiate between SGA and FGR in cases in which the fetal size is below the 10th percentile, additional biophysical parameters are required. Many methods have been proposed for this purpose, such as evaluation of fetal growth velocity, use of customized growth charts, Doppler velocimetric evaluation of placental and fetal circulations and use of biomarkers. Some of these biophysical parameters are also used to monitor fetal status and/or as delivery decision criteria. These Doppler velocimetric parameters are used to monitor fetal status and/or as delivery decision criteria, such as ductus venous velocimetry, biophysical profile (BPP) scoring and cardiotocographic (CTG) assessment of fetal heart rate short-term variation (STV), are not used as diagnostic criteria for FGR but for the surveillance and management of pregnancies already diagnosed as FGR, and are discussed below.

Tools for diagnosis, surveillance and management of fetal growth restriction

Fetal growth velocity

There are several methods to evaluate fetal growth velocity, including use of longitudinal growth charts, assessment of deviation from growth-velocity charts and individualized growth assessment. Overall, the objective is to evaluate the fetal growth trajectory and identify those fetuses that are deviating from their individual trajectory, indicating a failure to reach their growth potential. There is evidence to suggest that reduced fetal growth velocity in the third trimester is associated with increased risk of adverse outcome. Reduced growth velocity is normally taken to be a fall between consecutive ultrasound scans of 50 percentiles for AC or, more commonly, EFW.

Customized growth charts

In customized charts, the fetal weight and growth are adjusted for variables known to impact fetal size. These can include maternal height, weight, age, parity and ethnic and fetal sex. Adjustment for these variables is suggested to allow for better identification of SGA fetuses at risk of perinatal complications. Methods to evaluate fetal growth velocity and application of customized growth charts for this purpose are described in more detail in the ISUOG Guidelines on ultrasound assessment of fetal biometry and growth.

Doppler velocimetry

The rationale behind the application of Doppler velocimetry in fetal growth assessment is that it can identify uteroplacental function through evaluation of the uterine and umbilical arteries. Uteroplacental insufficiency is putatively mediated through spiral artery maladaptation and alterations in the villous vascular tree. On the fetal side, Doppler velocimetry allows evaluation of the middle cerebral artery (MCA) and ductus venosus as fetal cardiovascular adaptation progresses from hypoxia to acidemia.

A lack of physiological transformation of the uterine arteries from high- to low-resistance vessels is thought to reflect inadequate trophoblastic invasion of the spiral arteries, leaving a high-resistance circulation. The persistence of high uterine artery mean pulsatility index (PI) (above the 95th percentile) is associated with placental insufficiency and maternal vascular malperfusion of the placenta.

Progressively increasing PI in the UA corresponds to a progressive reduction in the placental surface area available for gas and nutrient exchange and increased fetal afterload resistance, and is associated with placental vascular insufficiency reflected by absent and, in the end-stage phase, reversed end-diastolic flow (EDF) in the UA.

Reduced fetal MCA-PI is a consequence of vasodilatation, the so-called ‘brain-sparing’ effect. This represents a hemodynamic response to fetal hypoxemia, via direct vascular sensing of oxygen tension in the cerebral circuit, and in other vascular beds a consequent redistribution of fetal cardiac output occurs preferentially to the coronary arteries and adrenal glands.

Alterations in the ductus venosus flow velocity waveform, especially absent or reversed a-wave, are
caused by progressive dilatation of the ductus venosus isthmus in order to increase the blood flow toward the heart, in an attempt to compensate for extreme oxygen deprivation. Others consider that absent or reversed a-wave in the ductus venosus is a consequence of increased intra-atrial pressure due to high cardiac afterload (increased vascular placental resistance) and/or a direct effect of fetal acidemia on myocardial cell function.

Doppler velocimetry plays a central role in identification, surveillance and management of FGR, because it allows for the identification of uteroplacental insufficiency and/or fetal cardiovascular adaptation to hypoxemia. Importantly, the two phenotypes of FGR, early-onset and late-onset, are characterized by different Doppler velocimetry patterns, as discussed below.

### Biophysical profile scoring

The BPP score consists of the combined evaluation of fetal tone, gross body movement, breathing movement, amniotic fluid volume and heart-rate reactivity. BPP score can predict both fetal pH and outcome. The relationship between altered BPP score and fetal pH seems to be consistent across gestational ages. A score of ≤ 4 is associated with a fetal pH ≤ 7.20, while a score of < 2 has a sensitivity of 100% for acidemia. This correlation remains highly significant even when using a simplified BPP that is based on assessment of only fetal heart rate and amniotic fluid volume.

### Cardiotocography and short-term variation

A reactive CTG virtually excludes fetal hypoxemia. The fetal heart rate STV is a biophysical parameter obtained by computerized CTG (cCTG) that reflects autonomic nervous system function. In the context of FGR and the accompanying presence of severe hypoxemia or hypoxia, the fetal sympathetic and parasympathetic activity is altered, resulting in reduced fetal heart rate variation, and, thus, reduced STV.

cCTG and evaluation of STV have been validated against invasive testing in fetal hypoxemia and acidemia and represent the only objective measure of fetal heart rate and amniotic fluid volume.

### Biomarkers

Placental biomarkers have a potential role in screening, diagnosis and therapy of placental disease linked to hypertensive disorders of pregnancy and/or FGR. Several placental factors have been investigated, including placental proteins as well as microRNA and mRNA. Some placental proteins, such as pregnancy-associated plasma protein-A, are biomarkers of placental function in the first trimester, though its predictive ability is limited.

The soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PIGF) ratio has been proposed as a short-term predictor to rule out pre-eclampsia in women in whom this condition is suspected. Although some reports suggest that use of the sFlt-1/PIGF ratio might be helpful in the management of and differentiation between SGA and FGR, the lack of interventional trial data precludes the recommendation of these tests as an adjunct to ultrasound imaging.

### Recommendations

- Fetal size alone is not sufficient to identify FGR, unless AC or EFW is below the 3rd percentile (GRADE OF RECOMMENDATION: C).
- A drop in fetal growth velocity, i.e. drop in AC or EFW of >2 quartiles or >50 percentiles (e.g. from 70th percentile to or below 20th percentile), should alert the physician to possible FGR (GRADE OF RECOMMENDATION: C).
- Doppler velocimetry of the uteroplacental and fetoplacental circulations may be used to distinguish between SGA and FGR (GOOD PRACTICE POINT).
- Multimodal assessment is recommended for the evaluation of pregnancies with suspected FGR. cCTG or BPP scoring should be used in combination with Doppler velocimetry (GRADE OF RECOMMENDATION: A).

### Definition of early-onset and late-onset fetal growth restriction

There are two main phenotypes of FGR which differ significantly in many aspects, such as prevalence, prediction by first-trimester ultrasound, gestational age at onset, placental histopathological findings, Doppler velocimetric profile, maternal associated disease, severity and perinatal outcome. Table 1 presents the main characteristics of the two phenotypes, which are defined as early-onset and late-onset FGR based on the observation that one phenotype is more frequent in early gestation and the second near term.

The distinction between early and late FGR is usually based on diagnosis before or after 32–34 weeks’ gestation. Although UA Doppler evaluation seems to discriminate better than gestational age between the two phenotypes of FGR with regards to their association with pre-eclampsia and adverse perinatal outcome, 32 weeks seems to be the optimal gestational-age cut-off at diagnosis and provides a reasonable classification of the two FGR phenotypes. This gestational-age threshold, therefore, is largely agreed upon as the main criterion to differentiate between early and late FGR and is used to distinguish between early- and late-onset FGR in this Guideline.

The definition of FGR varies between different guidelines and author groups. The criteria proposed...
Table 1: Main clinical characteristics of early- and late-onset fetal growth restriction (FGR)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Early-onset FGR</th>
<th>Late-onset FGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main clinical challenge</td>
<td>Management</td>
<td>Detection</td>
</tr>
<tr>
<td>Prevalence</td>
<td>30%</td>
<td>70%</td>
</tr>
<tr>
<td>Gestational age at manifestation</td>
<td>&lt; 32 weeks</td>
<td>≥ 32 weeks</td>
</tr>
<tr>
<td>Ultrasound findings</td>
<td>Fetus may be very small</td>
<td>Fetus not necessarily very small</td>
</tr>
<tr>
<td>Doppler velocimetry</td>
<td>Spectrum of Doppler alterations that involves umbilical artery, middle cerebral artery and ductus venosus</td>
<td>Cerebral blood-flow redistribution</td>
</tr>
<tr>
<td>Biophysical profile</td>
<td>May be abnormal</td>
<td>May be abnormal</td>
</tr>
<tr>
<td>Hypertensive disorders of pregnancy</td>
<td>Frequent</td>
<td>Not frequent</td>
</tr>
<tr>
<td>Placental histopathological findings</td>
<td>Poor placental implantation, spiral artery abnormalities, maternal vascular malperfusion</td>
<td>Less specific placental findings, mainly altered diffusion</td>
</tr>
<tr>
<td>Perinatal mortality</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Maternal cardiovascular hemodynamic status</td>
<td>Low cardiac output, high peripheral vascular resistance</td>
<td>Low</td>
</tr>
</tbody>
</table>

Table 2: Definitions for early- and late-onset fetal growth restriction (FGR) in absence of congenital anomalies, based on international Delphi consensus

**Early FGR:**
- GA < 32 weeks, in absence of congenital anomalies
- AC/EFW < 3rd centile or UA-AEDF

**Late FGR:**
- GA ≥ 32 weeks, in absence of congenital anomalies
- AC/EFW < 3rd centile
- Or at least two out of three of the following
  1. AC/EFW < 10th centile
  2. UtA-PI > 95th centile and/or
  3. UA-PI > 95th centile

*Growth centiles are non-customized centiles. AC, fetal abdominal circumference; AEDF, absent end-diastolic flow; CPR, cerebroplacental ratio; EFW, estimated fetal weight; GA, gestational age; PI, pulsatility index; UA, umbilical artery; UtA, uterine artery. Reproduced from Gordijn et al.16.

by an international Delphi consensus represent the most recognized definition of FGR (Table 2)16. In a recent validation study, the performance of these criteria was compared to that of a FGR definition of EFW < 10th percentile using the Hadlock growth standard, in predicting adverse neonatal outcome44. The study cohort spanned a wide gestational-age range and the two definitions had comparable performance, though the Delphi criteria were associated with an improved prediction of adverse neonatal outcome.

**Recommendations**

- The two main phenotypes of FGR, early and late, are characterized by different clinical, ultrasound and pathological characteristics (GRADE OF RECOMMENDATION: D).
- The authors of this ISUOG guideline recommend the Delphi consensus criteria16 for definition of FGR (GOOD PRACTICE POINT).

**Doppler velocimetry**

Despite the fact that Doppler velocimetry has been used in obstetric practice for nearly four decades, there is no universal agreement on which indices, thresholds and/or reference ranges to use. These considerations are not applicable when qualitative assessment is performed, such as evaluation of absent/reversed ductus venosus a-wave or absent/reversed EDF in the UA, but they affect Doppler velocimetry quantitative evaluation. International guidance on how to perform uteroplacental and fetal Doppler velocimetry is provided by ISUOG45.

There is considerable methodological heterogeneity in studies reporting reference ranges for MCA and UA Doppler indices and their ratio, which may, at least partly, explain the differences in reported reference ranges46. Even among studies with a high methodological quality score, there are significant differences in the definition of ‘normality’ and normal ranges46. A recent study evaluating the 10 most-cited articles providing reference ranges for MCA-PI, UA-PI and cerebroplacental ratio (CPR), found wide discrepancies in Doppler reference values that accounted for a variability of up to 50% in the 5th percentile cut-off value of MCA-PI at term47. Similarly, the study found significant differences in the cut-off for UA-PI above the 95th percentile (20–40%) and CPR below the 5th percentile (15–35%)47. Wide discrepancies have been reported in reference ranges used for biometry, Doppler parameters and birth weight, even at national level in centers with high expertise in the management of FGR, that might significantly impact the diagnosis and management of FGR48.
Another reason for the lack of standardization of quantitative Doppler velocimetry is that there is no uniformity in Doppler indices that are used, especially in research studies. For example, cerebral blood-flow redistribution can be defined as MCA-PI below different percentile thresholds (5th or 10th percentile), Z-scores or multiples of the median (MoM), or it can be defined as umbilicocerebral ratio (UCR) or CPR above or below different percentile thresholds, Z-scores or MoM, respectively 49. The Delphi consensus procedure identified CPR below the 5th percentile and UA-PI above the 95th percentile as Doppler criteria to define FGR 35. The rationale behind the application of the ratios of MCA-PI and UA-PI (CPR and UCR), instead of the individual components, is that they have been shown to be more sensitive to fetal hypoxia 50 and to be associated more strongly with adverse perinatal outcome 49,51. CPR is reported in studies more frequently than is UCR. A recent study suggested that UCR may allow for better differentiation of cases in the abnormal range in early FGR, as compared with CPR 52. However, it should be highlighted that there is no strong evidence in favor of either ratio.

The high variability in Doppler reference ranges and indices used has a major clinical impact on prenatal diagnosis, monitoring, timing of delivery decision, reproducibility and comparison of findings between research studies, efficacy of clinical policies and protocols, and many other aspects 46. The discussion about which reference ranges to use for the diagnosis and management of FGR is beyond the scope of this Guideline. However, these differences should be acknowledged and action is needed to homogenize the adoption of Doppler indices, thresholds and reference ranges in clinical and research practice. Table S1 summarizes the most relevant studies reporting reference charts for MCA and its ratios.

Early-onset fetal growth restriction

Early FGR is particularly associated with maternal vascular malperfusion of the placenta, characterized by abnormal transformation of the spiral arteries, pathologic features of the placental villi and multifocal infarction; these disease components result in so-called ‘placental insufficiency’ and form the most common basis for placenta-mediated FGR 33,34. Chronic ischemia of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placental villi impairs PI GF secretion and leads to excessive sFlt-1 release by syncytiotrophoblasts, thus of the placenta and umbilical cord, evaluated by Doppler velocimetry, can predict the fetal condition and are used for the management of early-FGR cases 36,38. Elevated Doppler UA-PI typically precedes a cascade of Doppler alterations, fetal heart rate changes and BPP modifications, with end-stage cardiovascular deterioration caused by severe hypoxemia followed by acidosis 35-37. Uterine artery, UA and MCA Doppler abnormalities represent early changes in early FGR and may be present for many weeks before severe cardiovascular and metabolic deterioration occurs. Although absent UA-EDF represents a progressive deterioration of uteroplacental function, it still precedes critical fetal deterioration, and the progression to reversed UA-EDF might be slow. However, the rate and rapidity of alteration in UA Doppler, from increased blood-flow resistance to absent EDF, determines the rate of fetal deterioration 56,58. The late deterioration of early FGR characterized by severe placental insufficiency is reflected by reversal of the EDF in the UA, and worsening generalized cardiovascular and metabolic failure reflected by alterations in the ductus venosus (absent or reversed a-wave) 37,59. This cardiovascular deterioration might precede or occur in parallel with the alteration of the STV, eventually manifesting as abnormal BPP score, spontaneous repetitive decelerations on CTG and stillbirth 39,60.

At present, there is no effective therapy for early FGR, though efficient recognition and management of severe pre-eclampsia may prolong some pregnancies with early FGR. The timely use of steroids, followed by magnesium sulfate, transfer to a tertiary care center and consideration of the safest mode of delivery, are the key concepts in early-FGR management 61. Ultimately, delivery represents the only therapeutic option in early FGR, in order to prevent severe consequences from hypoxia and acidosis that can lead to perinatal morbidity and mortality. On the other hand, the decision to deliver has to be balanced against the possible harm caused by prematurity 62,63. This is further complicated by the fact that the fetus is suffering from growth restriction, which is an independent risk factor for adverse outcomes associated with prematurity, thus making the outcome even more unfavorable 64,65. This is highlighted by the fact that, in fetuses with early FGR, neonatal survival first exceeds 50% after 26 weeks’ gestation, which is 2 weeks later than in their appropriate-for-gestational-age (AGA) counterparts 55. In this view, optimal monitoring and timing of delivery are of crucial importance when managing early FGR.

How to monitor

Once early FGR is suspected/diagnosed, the pregnancy should be monitored and managed in tertiary-level fetal medicine and neonatal units according to a uniform management protocol 66. Multidisciplinary counseling by neonatology and maternal–fetal medicine specialists is important. Evidence from a randomized trial (Trial of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE)) shows that monitoring and delivery timing according to a specific protocol including ductus venosus Doppler and cCTG provides better-than-expected outcomes 66. It should be taken into account that cCTG is not available or used universally. In that case, in addition to Doppler evaluation, assessment of conventional CTG and, where undertaken, BPP scoring should be performed 27. The loss of fetal gross body movement in association with ductus venosus Doppler index alterations can predict fetal cord pH < 7.20, while loss of fetal tone is associated with pH < 7.00 or a base excess < −12 mEq/L 27.
The surveillance frequency should be based on the severity of FGR and UA abnormalities. Progressive deterioration of UA Doppler velocimetry warrants more intensive monitoring every 2–3 days when absent or reversed UA-EDF is present. There is no consensus on monitoring frequency, however, suggested management strategies have been described elsewhere. MCA Doppler is one of the first parameters that becomes abnormal in early FGR. There seems to be a weak association between low MCA-PI and adverse short-term neonatal outcome and between low MCA-PI and high UCR and 2-year adverse neurodevelopmental outcome. However, gestational age at delivery and birth weight have the most pronounced impact on these outcomes. Thus, MCA Doppler seems to guide monitoring before 32 weeks of gestation but there is no evidence that it should be used to determine delivery timing.

Around 70% of women with early FGR will develop hypertensive disorders of pregnancy, mainly pre-eclampsia. Thus, regular blood-pressure assessment, and monitoring of urinary protein/creatinine ratio and baseline renal–hepatic function in asymptomatic women with early FGR are recommended. Although maternal PIGF testing might be useful, the value of biomarkers in the diagnosis and management of FGR in the absence of maternal hypertension remains undefined.

**Corticosteroid prophylaxis**

All available guidelines on early FGR recommend corticosteroid prophylaxis to prevent neonatal respiratory distress syndrome if the birth is likely to occur before 34 + 0 weeks. However, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends corticosteroid prophylaxis up to 35 + 6 weeks. Despite this recommendation, it is worth noting that no randomized trial has been performed in order to establish whether the benefits of corticosteroids in premature fetuses also apply to premature growth-restricted fetuses, in whom the reduced metabolism of corticosteroids by a smaller placenta and the already high level of endogenous adrenal corticosteroids might further damage the white matter of the brain and myelination. In fetuses with absent or reversed UA-EDF, enhanced daily surveillance is warranted during steroid administration.

**Magnesium sulfate prophylaxis**

There is good evidence for the efficacy of magnesium sulfate for fetal neuroprotection in the context of preterm delivery, however, the exact gestational-age threshold at which this attenuates remains unclear. Many guidelines and studies recommend magnesium sulfate prophylaxis for neuroprotection in growth-restricted fetuses, though the suggested time of commencement varies. In the absence of strong evidence regarding the optimum gestational age of magnesium sulfate prophylaxis that would allow for uniform application among countries, we recommend to refer to local or national guidelines.

**When and how to deliver**

A large prospective international multicenter study provided evidence that early gestational age at delivery and low birth weight are the primary quantifying parameters that adversely impact on the neonatal outcome of fetuses with early-onset FGR. Indeed, for extreme prematurity (< 27 weeks) and extremely low birth weight (< 600 g), each day of prolongation of the pregnancy improves neonatal survival by 2%. After 27 weeks, ductus venosus Doppler parameters emerged as the primary predictor of neonatal outcome.

The first randomized controlled trial on timing of delivery in FGR was the Growth Restriction Intervention Trial (GRIT). The study evaluated the effect of immediate delivery vs expectant management when the clinicians were uncertain about the optimal timing of delivery of a compromised fetus. The median time to delivery was 4.9 days in the expectant-management group compared with 0.9 days in the immediate-delivery arm, and there was no significant difference in neurodevelopmental outcome at 2 years or at school age between the two groups.

The TRUFFLE study is the largest randomized trial on timing of delivery in early FGR and was based on three randomization arms: early ductus venosus Doppler changes (PI > 95th percentile), late ductus venosus Doppler changes (a-wave at or below baseline) and reduced fetal heart rate STV on cCTG (< 3.5 ms before 29 weeks and < 4.0 ms thereafter). In addition, in all three arms, safety-net criteria were applied as an absolute indication for delivery, and were represented by spontaneous repeated persistent unprovoked fetal heart rate decelerations in all three arms or by STV < 2.6 ms at 26 + 0 to 28 + 6 weeks and < 3.0 ms at 29 + 0 to 31 + 6 weeks in the ductus venosus arms. The protocol recommended delivery if reversed UA-EDF occurred after 30 weeks or if there was absent UA-EDF after 32 weeks. Overall, the TRUFFLE study provided evidence that timing of delivery based on ductus venosus Doppler measurement in conjunction with cCTG safety-net criteria improves long-term (2-year) neurodevelopmental outcome in surviving infants. The cCTG STV ‘safety net’ was deliberately set at a level below that of the two ductus venosus randomized groups. Figure 1 presents the protocol recommended by the TRUFFLE study for monitoring and managing pregnancies with early FGR. Despite the fact that data from the TRUFFLE study showed better-than-expected results in terms of infant survival without neurological impairment (82% of children), the gestational age at study entry and at delivery and birth weight were strongly related to adverse outcome. It is important to highlight that outcomes similar to that of the TRUFFLE trial can be replicated only by using the monitoring strategy and delivery-decision criteria based on ductus venosus Doppler and cCTG in conjunction.

If cCTG is not available or not used, delivery timing should be based on combination of Doppler velocimetry indices (mainly ductus venosus before 30 weeks) and conventional CTG, or BPP where this is undertaken.
Considering the strong association with severe placental insufficiency and fetal hypoxemia/hypoxia, planned Cesarean section is indicated in the majority of early-onset cases of FGR. Importantly, delivery is indicated based on maternal indications, mainly hypertensive disorders of pregnancy, that could adversely impact the perinatal and maternal outcome."}

**Recommendations**

- Pregnancies with early FGR should be monitored and managed in tertiary-level units with the highest level neonatal care (GOOD PRACTICE POINT).
- Multidisciplinary management by neonatology and maternal–fetal medicine specialists is indicated (GOOD PRACTICE POINT).
- Multimodality assessment, including CTG and UA, MCA and ductus venosus Doppler evaluation, is recommended (GRADE OF RECOMMENDATION: A).
- When cCTG is available, STV should be the main parameter assessed (GRADE OF RECOMMENDATION: A).
- Monitoring should be scheduled based on the severity of FGR and alterations in UA Doppler (GOOD PRACTICE POINT).
- Delivery should be based on biophysical assessments or maternal indication, as follows:
  - At any gestational age: presence of maternal indication (e.g. severe pre-eclampsia, HELLP syndrome) or obstetric emergency requiring delivery (GOOD PRACTICE POINT);
  - 24 + 0 to 25 + 6 weeks: personalized management (GOOD PRACTICE POINT);
  - ≥ 26 + 0 weeks, deliver if any of the following is present:
    - Spontaneous repeated persistent unprovoked fetal heart rate decelerations (GRADE OF RECOMMENDATION: A);
    - Altered BPP (score ≤ 4) (GOOD PRACTICE POINT);
  - 26 + 0 to 28 + 6 weeks: deliver if ductus venosus a-wave is at or below baseline or STV < 2.6 ms (GRADE OF RECOMMENDATION: A);
  - 29 + 0 to 31 + 6 weeks: deliver if ductus venosus a-wave is at or below baseline or STV < 3.0 ms (GRADE OF RECOMMENDATION: A);
  - 32 + 0 to 33 + 6 weeks (permitted after 30 + 0 weeks): deliver if UA-EDF is reversed or STV < 3.5 ms (GOOD PRACTICE POINT);
  - ≥ 34 + 0 weeks (permitted after 32 + 0 weeks): deliver if UA-EDF is absent or STV < 4.5 ms (GOOD PRACTICE POINT).
- Corticosteroid prophylaxis is recommended if delivery is planned before 34 + 0 weeks of gestation (GRADE OF RECOMMENDATION: B).
Elective Cesarean delivery is recommended if one or more of the following is present: abnormal CTG STV, ductus venosus Doppler alteration, absent or reversed UA-EDF, altered BPP, maternal indication (GOOD PRACTICE POINT).

Late-onset fetal growth restriction

The pathophysiology of late FGR differs from that of early FGR. Late FGR is characterized by milder and more aspecific placental lesions and/or alteration in oxygen and nutrient diffusion. Consequently, alterations in UA Doppler and venous districts are rare and fail to identify the vast majority of late-FGR cases or to predict adverse outcome in these fetuses. Several studies have found an association between MCA vasodilatation (i.e. reduction in MCA-PI) or the alteration of its ratio with UA-PI and poorer perinatal outcome, including stillbirth, higher risk of Cesarean delivery, and increased risk of abnormal neurodevelopment at birth and at 2 years of age. The rationale for using the ratios of MCA-PI and UA-PI (CPR and UCR) is that they can identify subtle changes between placental and cerebral blood-flow perfusion that may not be appreciated by evaluation of a single parameter. Furthermore, it has been suggested that evaluation of the CPR may improve the prediction of adverse perinatal outcome in growth-restricted fetuses. The biophysical abnormalities that characterize late FGR include alteration of fetal breathing, decreased amniotic fluid volume and loss of fetal heart rate reactivity on conventional CTG. However, in fetuses with late FGR, it seems that BPP becomes abnormal only shortly before stillbirth, and therefore, it is not useful in the determination of monitoring intervals.

Despite presenting with milder clinical form than early FGR, late FGR is still associated with poor perinatal outcome and longer-term educational attainment. In the TRUFFLE study, the risk of poor neurodevelopmental outcome in babies that were delivered after 32 weeks’ gestation remained static until term. This may be due to several factors. The pathophysiology of late FGR is still not completely understood and this may determine a lower identification rate of fetuses exposed to growth restriction near term. Moreover, fetuses near term seem to have reduced tolerance to hypoxemia, possibly because of their relatively high metabolic rate, compared with fetuses at an earlier gestation. Thus, frequent monitoring of pregnancies with late FGR is warranted in the same way as for those with early FGR.

How to monitor

At present, MCA-PI and its ratios to UA-PI are the most important Doppler parameters in the surveillance of late FGR. In the presence of UA-PI > 95\textsuperscript{th} percentile, monitoring at least once or twice a week is indicated. A large retrospective study showed that, in FGR pregnancies after 34 + 0 weeks of gestation, the median interval between a low MCA-PI and stillbirth was ≤5 days, suggesting that, if delivery has not been indicated by that time, twice-weekly Doppler surveillance may be required after 34 weeks. Moreover, in the same study, almost 90% of stillbirths occurred within 1 week of a normal BPP score in the presence of cerebral vasodilatation, suggesting that BPP may have poor value in determining the frequency of fetal monitoring.

Considering the fact that some concerns have been raised regarding the interobserver reliability of MCA-PI measurement, when alteration in MCA-PI, CPR or UCR is encountered, the measurement should be confirmed within 24 h to avoid false-positive results, especially when timing of delivery is based on this finding.

Corticosteroid prophylaxis

There is no lack of consensus between guidelines with respect to corticosteroid prophylaxis between 34 and 36 weeks’ gestation. Most guidelines on FGR recommend corticosteroid prophylaxis if the birth is likely to occur before 34 + 0 weeks, however, the RCOG recommends corticosteroid prophylaxis up to 35 + 6 weeks.

When and how to deliver

There is no international consensus on the timing of delivery in late FGR, due to the lack of interventional management randomized trials based on Doppler indices in these pregnancies. In fact, national guidelines for the management of FGR are highly variable. The only randomized interventional trial on FGR at or close to term is the Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT) study. The study compared the effect of induction of labor vs expectant monitoring in singleton pregnancies beyond 36 + 0 weeks of gestation with suspected FGR. The study did not take into account any Doppler assessment and the only Doppler parameter reported was absent EDF in the UA (present in 14/650 pregnancies). The induction-of-labor policy, compared with expectant management, did not affect the rate of adverse neonatal outcome or neurodevelopmental and behavioral outcome at 2 years of age, except for in children with birth weight below the 2.3\textsuperscript{rd} percentile. Moreover, it did not affect the rates of instrumental vaginal delivery and Cesarean section. In the induction-of-labor group, more neonates were admitted to intermediate-level care, but this outcome was reduced when considering only induction after 38 weeks of gestation. Importantly, the proportion of neonates with birth weight below the 3\textsuperscript{rd} percentile was greater in the expectant-monitoring arm, as was the proportion of women who developed pre-eclampsia. Based on these findings, it would appear that induction of labor for suspected FGR after 38 weeks’ gestation is not associated with increased incidence of instrumental vaginal delivery or Cesarean section, or...
adverse neonatal or 2-year child outcome, while it seems to be associated with decreased incidence of neonates with extremely low birth weight and of progression to pre-eclampsia. Of note, fetuses at term with birth weight below the 3rd percentile have the highest risk of stillbirth, approximately 1:100\(^{12}\) hence these pregnancies should not exceed 37 + 6 weeks of gestation, independent of Doppler findings. All cases of stillbirth in the DIGITAT trial occurred among women who, despite meeting the inclusion criteria, declined to participate (approximately 1%, pers. comm.). This stresses the importance of monitoring growth-restricted fetuses at or near term, and timely delivery.

In pregnancies with late FGR and UA-PI above the 95\(^{\text{th}}\) percentile, expert opinion is that delivery should be considered when the gestation is beyond 36 + 0 weeks and not later than 37 + 6 weeks\(^{105}\).

Though cerebral redistribution is associated with adverse short- and long-term perinatal outcome\(^{49,106–108}\), there is currently no evidence as to how cerebral Doppler should be utilized in the delivery timing of FGR. However, it seems reasonable that, in pregnancies with late FGR and signs of cerebral blood-flow redistribution, delivery should be considered at around 38 + 0 weeks and not later than 38 + 6 weeks. It is important that each unit predisposes and follows a precise dedicated monitoring protocol, based also on local experience and resources.

Depending on the clinical situation (parity, EFW, cervical findings), induction of labor may be undertaken, but this is not recommended in the context of critical UA Doppler findings (i.e. absent or reversed EDF)\(^{43,105}\). Continuous fetal heart rate monitoring during labor should be undertaken. Figure 2 summarizes the proposed management of FGR pregnancies based on cCTG and Doppler findings.

### Recommendations

- In pregnancies with late FGR, delivery should be based on biophysical assessments or maternal indication as follows:
  - At any gestational age, deliver if one of the following is present:
    - Spontaneous repeated persistent unprovoked fetal heart rate decelerations (GOOD PRACTICE POINT);
    - Altered BPP (score ≤ 4) (GOOD PRACTICE POINT);
    - Maternal indication (e.g. severe pre-eclampsia, HELLP syndrome) or obstetric emergency requiring delivery (GOOD PRACTICE POINT);
    - cCTG STV < 3.5 ms at 32 + 0 to 33 + 6 weeks and < 4.5 ms at ≥ 34 + 0 weeks (GOOD PRACTICE POINT);
    - Absent or reversed UA-EDF (GOOD PRACTICE POINT);
  - 36 + 0 to 37 + 6 weeks: deliver if UA-PI > 95\(^{\text{th}}\) percentile or AC/EFW < 3rd percentile (GOOD PRACTICE POINT);
  - 38 + 0 to 39 + 0 weeks: deliver if there is evidence of cerebral blood-flow redistribution or any other feature of FGR (GOOD PRACTICE POINT).

- In the absence of contraindications, induction of labor is indicated (GOOD PRACTICE POINT).
- During labor, continuous fetal heart rate monitoring is recommended (GOOD PRACTICE POINT).

### Small-for-gestational age

SGA is often considered as a constitutionally small fetus that is otherwise healthy; it is frequently the case that

---

Figure 2: Recommended management of pregnancies with fetal growth restriction (FGR), based on computerized cardiotocography and Doppler findings. \(*\)Permitted after 30 + 0 weeks. \(†\)Permitted after 32 + 0 weeks. AC, fetal abdominal circumference; AEDF, absent end-diastolic flow; DV, ductus venosus; EFW, estimated fetal weight; PI, pulsatility index; REDF, reversed end-diastolic flow; STV, short-term variation; UA, umbilical artery; wks, gestational weeks.

---

Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2020; 56: 298–312.
the SGA categorization is applied to a small baby that is structurally normal and has normal Doppler findings. In these cases, the adoption of customized growth charts has been suggested to reduce the proportion of SGA. However, there is evidence suggesting that SGA with normal fetoplacental Doppler can be associated with accelerated placental aging, signs of placental underperfusion, lower umbilical vein blood flow volume, altered maternal hemodynamics and greater incidence of Cesarean section for fetal distress compared with AGA fetuses. Such evidence poses the question as to whether there might be a subgroup of SGA fetuses that do in fact suffer from ‘stunted’ fetal growth, which adapt to a poor nutritional environment and are not identified by standard biophysical diagnostic tools. Further research is needed to better understand this hypothesis.

How to monitor

At the diagnosis of SGA, fetal Doppler indices (UA-PI, MCA-PI and their ratios) and uterine artery Doppler should be evaluated. In the case of late SGA (after 32 weeks), once uterine artery Doppler has been assessed at diagnosis, there is no need for uterine artery Doppler to be re-evaluated at each visit as, usually, it remains unchanged from diagnosis of SGA to delivery. Fortnightly assessment of fetal growth is recommended. Late-SGA fetuses with abnormal uterine artery PI at diagnosis, compared to those without, are more likely to progress to brain sparing, in other words ‘cross over’ to FGR, and this usually occurs at earlier gestational-age epochs. Even late-SGA fetuses with normal uterine artery PI can progress to brain sparing, albeit less frequently and 1–2 weeks later than fetuses with abnormal uterine artery PI.

When and how to deliver

Reports suggest that universal induction of labor at term may be more beneficial than expectant management in terms of reduced perinatal mortality, without increasing the rate of Cesarean section or operative vaginal delivery. This is true for both nulliparous women aged ≥35 years and unselected populations. Considering that the major cause of perinatal death at term is stillbirth and that some SGA fetuses might suffer some degree of stunted growth that is not adequately identified by current biophysical tools, it is reasonable to consider delivery after 38 + 0 weeks of gestation, and the pregnancy should not exceed 39 + 0 weeks, in order to reduce the risk of severe growth restriction or stillbirth in fetuses identified as SGA. This recommendation is also supported by the findings of the DIGITAT study. Induction of labor is appropriate depending on the clinical situation, and continuous fetal heart rate monitoring in labor should be performed in these cases.

Recommendations

- Fetal Doppler velocimetry should be performed both at the diagnosis of SGA and during follow-up (GOOD PRACTICE POINT).
- In case of late SGA, fortnightly assessment of fetal growth and weekly assessment of UA-PI, MCA-PI, CPR and UCR is recommended (GOOD PRACTICE POINT).
- When SGA has been identified, delivery should be planned from 38 + 0 weeks and the pregnancy should not exceed 39 + 0 weeks of gestation (GRADE OF RECOMMENDATION: A).
- Continuous fetal heart rate monitoring during labor is indicated (GOOD PRACTICE POINT).

What is not known and implications for research

The Delphi consensus on the criteria for FGR diagnosis is of importance as it has established a uniform definition of early and late FGR. However, it is still not clear whether a proportion of fetuses with AC or EFW below the 10th percentile (namely SGA) with normal umbilical and cerebral Doppler indices might suffer from stunted fetal growth as suggested by recent findings. This question warrants further exploration. It is hypothesized that even before the signs of hypoxemia establish, there is a ‘preclinical’ phase during which the fetus is exposed to a reduced supply of nutrients and oxygen to which it responds by reduced growth and oxidative metabolism. There are several hypotheses regarding the underlying pathophysiological processes of fetal growth impairment, such as inadequate maternal perfusion of the uterus due to overruns of the maternal hemodynamic adaptation potential, overrun of the placental potential in response to increasing fetal needs, or placental senescence due to oxidative stress. It may be that UA Doppler alterations and signs of cerebral blood-flow redistribution are not sophisticated enough to capture and discriminate these imbalances between fetal needs and maternal and/or placental potential before hypoxemia establishes. In this respect, more efforts should be made to identify potential predictors of the subgroup of SGA fetuses that is at increased risk of perinatal and long-term adverse outcomes. New emerging biophysical and biochemical tools, such as alternative analysis of fetal heart rate acceleration and deceleration parameters, evaluation of maternal hemodynamics, evaluation of umbilical vein blood-flow volume and even assessment of uterine blood-flow volume could help to disentangle the different aspects of SGA and FGR.

The finding that sFlt-1/PlGF ratio can predict the short-term presence or absence of pre-eclampsia opens the possibility that placental protein markers can provide considerably enhanced screening test precision to distinguish the healthy SGA fetus from the fetus with placenta-mediated FGR that is at risk of stillbirth and asphyxia-related morbidity. In women with hypertensive disorders, the sFlt-1/PlGF ratio has been shown to be able to differentiate cases with pre-eclampsia and SGA from...
those with pre-eclampsia and AGA fetuses\textsuperscript{126}, and this should be explored further in pregnant patients monitored for SGA and/or FGR\textsuperscript{34}.

Early FGR is associated with complications related to prematurity, as preterm birth is often necessitated to prevent stillbirth. There is a strong desire to delay progression of the condition once the diagnosis is made. Attempts have been made by several research groups (STRIDER (Sildenafil TherapY In Dismal prognosis Early-onset intrauterine growth Restriction) consortium) to evaluate the role of sildenafil, a phosphodiesterase Type-5 inhibitor, in improving the outcome of fetuses with early FGR. It is believed that its potential vasodilatory effect on the uterine vessels might improve fetal growth in utero. The UK-based randomized placebo-controlled trial demonstrated that administration of sildenafil at a dose of 25 mg three times daily (\(n = 70\)) vs placebo (\(n = 65\)) does not prolong the pregnancy or improve outcomes in severe early-onset FGR diagnosed between 22 + 0 and 29 + 6 weeks of gestation\textsuperscript{127}. A similar trial from New Zealand and Australia, including 122 cases of early FGR, demonstrated that maternal use of sildenafil has no effect on fetal growth velocity\textsuperscript{128}. Significant concerns regarding the safety of sildenafil during pregnancy were raised following an excess of neonatal deaths due to pulmonary hypertension in one trial based in The Netherlands, and it is currently recommended that sildenafil should not be used in FGR outside the setting of high-quality randomized clinical trials\textsuperscript{129}.

Several novel approaches are being investigated for improving the outcome of pregnancies with early-onset FGR. The EVERREST (doEs Vascular endothelial growth factor gene therapy safEly impRove outcome in seveRe Early-onset fetal growth reStriction?) group\textsuperscript{125} is planning an uncontrolled open-label trial in pregnancies affected by early FGR in order to evaluate the efficacy of localized injected maternal vascular endothelial growth factor gene therapy to improve fetal growth. Given that high maternal vascular resistance and low cardiac output are characteristic in early FGR, vasodilator agents and increasing intravascular volume have been suggested to improve fetal growth and prolong gestation\textsuperscript{130}. Importantly, therapies for maternal hypertension that reduce cardiac output, such as beta blockers, have been linked to poor perinatal outcome and stillbirth and should be used with caution in these cases.

Besides the need for homogeneous application of Doppler indices, thresholds and reference ranges, the question regarding their clinical utility for monitoring and timing delivery in FGR pregnancies diagnosed > 32 weeks’ gestation is still to be answered. The evidence of association between signs of cerebral blood-flow redistribution and adverse pregnancy outcome is based mainly on retrospective and observational studies, in which the application of Doppler indices might have influenced pregnancy management and outcome, and therefore introduced bias. Currently, there is no randomized interventional trial on the utility of Doppler parameters in timing delivery in late FGR. Thus, the key research question is whether early delivery of fetuses with late FGR and signs of cerebral blood-flow redistribution is beneficial (by removing the fetus from exposure to a hostile environment and hypoxemia) or harmful (by inducing late prematurity). A study of this kind should address the issues of perinatal morbidity and mortality, as well as long-term neurodevelopmental outcomes. Moreover, it is not clear which monitoring policy is most beneficial and which Doppler parameters and thresholds perform best in late FGR. Ongoing randomized controlled trials on this topic will provide answers to these important questions.

**CONCLUSION**

Early diagnosis, close follow-up and timely delivery of pregnancies with FGR are of crucial importance for perinatal short- and long-term outcome. The identification of FGR is not always straightforward, for several reasons. First, a single biometric measurement of fetal size is not sufficient to evaluate fetal growth, except perhaps in the case of extremely small fetal size. Thus, additional biophysical tools and/or evaluations are needed in order to identify FGR. Second, there are two phenotypes of FGR that differ significantly in many aspects. Knowledge of the clinical manifestation and progress of early-onset and late-onset FGR is of crucial importance for all aspects of management (from diagnosis to delivery). At present, the most recognized criteria to define early and late FGR are those derived from an international Delphi survey consensus\textsuperscript{10}.

Once the diagnosis of FGR has been made, multimodal assessment (including Doppler velocimetry, cCTG and BPP), which may differ between countries, is recommended. Early FGR is associated more strongly with abnormal trophoblastic invasion and consequent placental insufficiency. The risk of perinatal mortality and morbidity and long-term adverse outcome is very high in these pregnancies, and depends both on the severity of growth restriction and prematurity. For this reason, pregnancies with early FGR should be managed in multidisciplinary tertiary-level units. Despite the severity of early FGR, the cascade of Doppler alterations is quite well-known and randomized controlled trials have provided a robust level of evidence for delivery criteria.

Late FGR has a milder clinical presentation than does early FGR, and hence, it is not associated with severe prematurity but can still be associated with significant morbidity. Despite that, at present, the diagnosis and management of late FGR, especially near term, is complex. The assessment of MCA-PI and its ratios to UA-PI have a central role in the identification of late FGR. However, there is no clear evidence as to whether the decision to deliver based on Doppler evaluation of cerebral blood-flow redistribution might be beneficial in terms of short- and long-term neurodevelopmental outcome and which is the optimal gestational age at which to deliver these pregnancies.

In conclusion, the diagnosis and management of FGR pregnancies still pose some concerns and dilemmas. In
fact, there is some evidence that even SGA fetuses with normal Doppler velocimetry might suffer some degree of growth restriction not identifiable by standard biophysical tools. New technologies and tools might be helpful in differentiating between SGA and FGR, and randomized controlled trials on management that are in progress will hopefully provide clear evidence on some unanswered questions. The real challenge remains to determine whether therapeutic intervention in FGR will ever be feasible.

GUIDELINE AUTHORS

This Guideline was produced on behalf of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) by the following authors, and peer reviewed by the Clinical Standards Committee.

C. C. Lees, Centre for Fetal Care, Queen Charlotte’s and Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK; and Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; and Department of Development & Regeneration, KU Leuven, Leuven, Belgium

T. Stampalija, Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; and Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy

A. A. Baschat, Johns Hopkins Center for Fetal Therapy, Departments of Gynecology & Obstetrics and Pediatric Surgery, Johns Hopkins University, Baltimore, MD, USA

F. da Silva Costa, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; and Department of Obstetrics and Gynecology, School of Clinical Sciences, Monash University, Victoria, Australia

E. Ferrazzi, Department of Woman, Child and Neonate, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

F. Figueras, Fetal Medicine Research Center, BCNatal Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Ciutat de Ginecologia, Obstetricia i Neonatologia, University of Barcelona, Barcelona, Spain

K. Hecher, Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

J. Kingdom, Placenta Program, Maternal-Fetal Medicine Division, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

L. C. Poon, Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong SAR

L. J. Salomon, Obstétrique et Plateforme LUMIERE, Hôpital Necker-Enfants Malades (AP-HP) et Université de Paris, Paris, France

J. Unterschneider, Department of Maternal Fetal Medicine, Royal Women’s Hospital, Melbourne, Victoria, Australia; and Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia.

CITATION


REFERENCES


APPENDIX 1 Levels of evidence and grades of recommendation used in ISUOG Guidelines

### Classification of evidence levels

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>++</td>
<td>High-quality meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with very low risk of bias</td>
</tr>
<tr>
<td>+</td>
<td>Well-conducted meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with low risk of bias</td>
</tr>
<tr>
<td>1</td>
<td>Meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with high risk of bias</td>
</tr>
<tr>
<td>2++</td>
<td>High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with very low risk of confounding, bias or chance and high probability that the relationship is causal</td>
</tr>
<tr>
<td>2+</td>
<td>Well-conducted case–control or cohort studies with low risk of confounding, bias or chance and moderate probability that the relationship is causal</td>
</tr>
<tr>
<td>2</td>
<td>Case–control or cohort studies with high risk of confounding, bias or chance and significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>3</td>
<td>Non-analytical studies, e.g. case reports, case series</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

### Grades of recommendation

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta-analysis, systematic review or randomized controlled trial rated as 1++ and directly applicable to the target population; or systematic review of randomized controlled trials or body of evidence consisting principally of studies rated as 1++ applicable directly to the target population and demonstrating overall consistency of results</td>
</tr>
<tr>
<td>B</td>
<td>Body of evidence including studies rated as 2++ applicable directly to the target population and demonstrating overall consistency of results; or evidence extrapolated from studies rated as 1++ or 1+</td>
</tr>
<tr>
<td>C</td>
<td>Body of evidence including studies rated as 2++ applicable directly to the target population and demonstrating overall consistency of results; or evidence extrapolated from studies rated as 2++</td>
</tr>
<tr>
<td>D</td>
<td>Evidence of level 3 or 4; or evidence extrapolated from studies rated as 2+</td>
</tr>
</tbody>
</table>

Good practice point: Recommended best practice based on clinical experience of the Guideline Development Group

**SUPPORTING INFORMATION ON THE INTERNET**

The following supporting information may be found in the online version of this article:

Table S1 Most relevant studies reporting reference ranges for fetal middle cerebral artery (MCA), cerebroplacental ratio (CPR) and umbilicocerebral ratio (UCR). Adapted from Ruiz-Martinez et al.47

---

Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd. *Ultrasound Obstet Gynecol* 2020; 56: 298–312.